The immunology of Leishmania infection and the implications for vaccine development

Annals of the New York Academy of Sciences

Volumn 1026, Issue , 2004, Pages 267-272

  Vanloubbeeck, Yannick ^a   Jones, Douglas E ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

Immune; Leishmania; T cell; Vaccine

Indexed keywords

BCG VACCINE; DNA VACCINE; FLT3 LIGAND; GAMMA INTERFERON; INACTIVATED VACCINE; LEISHMANIA VACCINE; LIVE VACCINE; OLIGONUCLEOTIDE;

ANIMAL MODEL; ANTIGEN SPECIFICITY; CONFERENCE PAPER; CPG ISLAND; CYTOKINE PRODUCTION; DENDRITIC CELL; DOG; GENE DELETION; HOST PARASITE INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOMODULATION; INFECTION PREVENTION; INFECTION RESISTANCE; LEISHMANIA; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE TRANSMISSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; VACCINATION;

ANIMALIA; CANIS FAMILIARIS; MYCOBACTERIUM BOVIS BCG; PHLEBOTOMINAE; PROTOZOA;

EID: 10444254809     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1307.041     Document Type: Conference Paper

References (30)

1. CENTER FOR DISEASE CONTROL AND PREVENTION, N.C.F.I.D., Division of Parasitic Diseases, Leishmania Infection; Fact Sheet. 2000. www.CDC.gov.
2. MAGILL, A.J., M. GROGL, R.A. GASSER JR., et al. 1993. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N. Engl. J. Med. 328: 1383-1387.
3. BARRAL, A., D. PEDRAL-SAMPAIO, G. GRIMALDI JUNIOR, et al. 1991. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am. J. Trop. Med. Hyg. 44: 536-46.
4. GRADONI, L. 2001. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet. Parasitol. 100: 87-103.
5. DAVIES, C.R., P. KAYE, S.L. CROFT & S. SUNDAR. 2003. Leishmaniasis: new approaches to disease control. Br. Med. J. 326: 377-382.
6. SACKS, D. & N. NOBEN-TRAUTH. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2: 845-858.
7. MELBY, P.C. 2002. Recent developments in leishmaniasis. Curr. Opin. Infect. Dis. 15: 485-490.
8. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168: 3992-4000.
9. + T cells following secondary infection of mice immune to Leishmania major. Infect. Immun. 62: 2575-2581.
10. MENDEZ, S., S. GURUNATHAN, S. KAMHAWI, et al. 2001. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166: 5122-5128.
11. COLMENARES, M., P.E. KIMA, E. SAMOFF, et al. 2003. Perforin and gamma interferon are critical CD8(+) T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect. Immun. 71: 3172-3182.
12. MOSER, M. & K.M. MURPHY. 2000. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 1: 199-205.
13. MEDZHITOV, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145.
14. BANCHEREAU, J., F. BRIERE, C. CAUX, et al. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18: 767-811.
15. GUERMONPREZ, P., J. VALLADEAU, L. ZITVOGEL, et al. 2002. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20: 621-667.
16. RUSSO, D.M., M. BARRAL-NETTO, A. BARRAL & S.G. REED. 1993. Human T-cell responses in Leishmania infections. Prog. Clin. Parasitol. 3: 119-144.
17. KAYE, P.M., A.J. CURRY & J.M. BLACKWELL. 1991. Differential production of Th1-and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146: 2763-2770.
18. AFONSO, L.C. & P. SCOTT. 1993. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61: 2952-2959.
19. JI, J., J. SUN, H. QI & L. SOONG. 2002. Analysis of T helper cell responses during infection with Leishmania amazonensis. Am. J. Trop. Med. Hyg. 66: 338-345.
20. JONES, D.E., L.U. BUXBAUM & P. SCOTT. 2000. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J. Immunol. 165: 364-372.
21. HANDMAN, E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14: 229-243.
22. MANICKASINGHAM, S.P., A.D. EDWARDS, O. SCHULZ & C. REIS E SOUSA. 2003. The ability of murine dendritic cell subsets to direct T helper cell differentiation is dependent on microbial signals. Eur. J. Immunol. 33: 101-107.
23. SKEIKY, Y.A., M. KENNEDY, D. KAUFMAN, et al. 1998. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161: 6171-6179.
24. BERBERICH, C., J.R. RAMIREZ-PINEDA, C. HAMBRECHT, et al. 2003. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J. Immunol. 170: 3171-3179.
25. COLER, R.N., Y.A. SKEIKY, K. BERNARDS, et al. 2002. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70: 4215-4225.
26. MARASKOVSKY, E., K. BRASEL, M. TEEPE, et al. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184: 1953-1962.
27. KREMER, I.B., M.P. GOULD, K.D. COOPER & F.P. HEINZEL. 2001. Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice. Infect. Immun. 69: 673-680.
28. STEINMAN, R.M. & M. POPE. 2002. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109: 1519-1526.
29. KAMHAWI, S. 2000. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections. Microbes Infect. 2: 1765-1773.
30. VALENZUELA, J.G., Y. BELKAID, M.K. GARFIELD, et al. 2001. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J. Exp. Med. 194: 331-342.